Peginterferon Alfa-2b in Treating Younger Patients With Craniopharyngioma That is Recurrent or Cannot Be Removed By SurgeryProspective Pilot Study Identifying Clinically Relevant Biological Targets for Medical TherapyIspinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or LymphomaVorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord TumorsNeuromodulation for Hypothalamic ObesityPositron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain TumorsA Phase II Trial of Limited Surgery and Proton Therapy for Craniopharyngioma or Observation After Radical ResectionExamination of Sleep and Family Functioning in Pediatric Craniopharyngioma PatientsProspective Study of Children and Adolescents With CraniopharyngiomaRO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant GliomaGamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell LeukemiaVemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive CraniopharyngiomaMemantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain TumorsAn Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic InjuryWeight Gain in Surgically Treated Adult-onset CraniopharyngiomaEffect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar LesionsEfficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain TumorsWeight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor1.5T Intraoperative MR Imaging in CraniopharyngiomasTumor Classification and Its Application in Surgical Treatment of CraniopharyngiomaABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS TumorsCollecting and Storing Tissue From Young Patients With CancerCollecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain TumorsHypothalamic Obesity Following Craniopharyngioma Surgery: A Pilot Trial of Combined Metformin and Diazoxide TherapyVorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and LymphomaMethionine PET/CT Studies In Patients With CancerSleep Wake and Melatonin Pattern in CraniopharyngiomaSCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain TumorsStereotactic Radiosurgery in Treating Patients With Brain TumorsEffect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary LesionsObservation of Young Patients Who Are Undergoing Surgery for CraniopharyngiomaLenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS TumorsCilengitide in Treating Children With Refractory Primary Brain TumorsFR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaIrinotecan in Treating Children With Refractory Solid TumorsTemozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain TumorsTocilizumab in Children With ACPSocial Participation After Childhood CraniopharyngiomaEfficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma TherapyIntranasal Oxytocin in Hypothalamic Obesity
P1050
Q61864788-0677D43E-78F7-4AB0-9FCE-5C02434D7352Q61906838-13702BF2-DDF8-42D0-802A-202E0177B53CQ61934710-E7B858AA-1691-4635-BCFF-DDEDA6817409Q61938124-6FD66C52-62FF-4290-8C70-243E6EA94BA5Q62042363-9A30BE59-0132-4D2D-B2D3-3916A14B09B2Q62105305-3DE87120-18E6-4CE3-BB11-4D6074FCD079Q63322513-C354CA23-D9B5-4FBD-8390-0DD4B998CD2CQ63533898-FC7BA180-C3FF-44C0-A151-0F2B7B085FC7Q63815619-EBDFA341-86A1-4225-BB01-6269045393FFQ63830534-4D66A71B-9CD1-4453-8B28-37DF08A25852Q63836089-D60E6025-42C5-4B20-BC3C-87D3F513C2FFQ64122652-4E98E3E0-645A-4DDA-9809-2D0CA1F25544Q64172583-D792AF1D-BA7C-471C-AC5B-EAC5A33708E0Q64223261-F9FD5FB9-9A54-4309-811A-A7FE03BA9573Q64352928-7673B480-E42A-41B1-A9E3-009EE0DDA396Q64607536-D12D90A4-D0F0-4E49-9CB2-1674FCADC0B2Q64610647-9F86960B-662C-4D51-AF00-62034D595740Q64646988-B3C3DBBD-84DA-4C05-841C-3DB67A2AD875Q64654407-77FF3E5F-8B4A-4AAB-98D8-CB2FB3DB657DQ64665157-B6BC0A08-DFB1-4570-AF8B-4394CCE88995Q64665371-34D3D1B5-B95B-40AA-8DDB-41FD1A6EBC96Q64676309-0366FA71-898F-49E0-96F1-150BA232289DQ64676850-C8F3E22E-AD34-48AC-B397-A1F0B3BBFDB8Q64677910-72FAD3F9-9D0B-4CC3-99BC-ABAB323F301CQ64693251-70688769-066F-4D7E-B746-751A6CF48D86Q64693666-D4C1D40D-FF72-4BBD-B696-F51238A8B960Q65362611-2D9352F7-E480-47BB-8E64-52262D96AC0DQ65383090-A33CF4A1-49F4-45D2-B91F-26CA34DB8021Q65385220-D471B3CA-4CE8-4A69-84E9-AE92D5B2D18CQ65474434-50AFE94C-D395-4611-9870-82324576013CQ65540093-8E7A1779-D711-4BCA-A040-33BDA58F2568Q66033663-AB37F3B8-92C7-4800-87DD-A1D9E1607E6AQ66035700-134B2B96-ECA3-4D42-8D87-95689AAF6C4DQ66037421-CB8E4DEE-0CAB-41C2-ADB0-9D0074D289E4Q66037557-3CF6EC07-8CBC-431B-B758-6A08842166ABQ66037579-39ADF9F2-2281-4AFC-BFBF-62FF00C252ACQ66065297-E5F0310E-949A-45D5-BF72-271743EA911EQ66070992-1B237EB5-C65F-4894-9F29-7437FAEE230FQ66394779-992D3E22-A9B0-4DA1-BE46-3D3C5EDFCDC8Q66396838-2C9AF224-24B3-4271-804C-3F9D9EA5151B
P1050
description
Krankheit
@de
bone cancer that is located in almost exclusively in the long bones
@en
tumeur osseuse bénigne
@fr
tumore maligno delle ossa lung ...... re e nella diafisi della tibia
@it
name
Adamantinoma
@es
Adamantinoma
@nl
adamantinoma
@en
adamantinoma
@it
adamantinoma
@pt
adamantinome
@fr
ადამანტინომა
@ka
type
label
Adamantinoma
@es
Adamantinoma
@nl
adamantinoma
@en
adamantinoma
@it
adamantinoma
@pt
adamantinome
@fr
ადამანტინომა
@ka
altLabel
Epitelioma adamantino
@it
prefLabel
Adamantinoma
@es
Adamantinoma
@nl
adamantinoma
@en
adamantinoma
@it
adamantinoma
@pt
adamantinome
@fr
ადამანტინომა
@ka
P486
P6366
P646
P1296
P1550
P1748
P1995
P279
P2892
P31
P373
Adamantinoma
P486
P492
P563
P6366
2780443816
P646
/m/0273j2r
P672
C04.588.149.030
C05.116.231.030